Skip to main content
OpenTrials

Clinical trial condition

Urologic Neoplasms

Explore clinical trials studying Urologic Neoplasms. Study availability and eligibility vary by location and protocol.

2,952 public trials 630 recruiting studies
Refine in advanced search Browse all conditions

Urologic Neoplasms trial results

Active, Not Recruiting

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

NCT05078047

Conditions
Adenocarcinoma, Basal Cell Carcinoma, Breast Diseases, +69 more
Locations
  • Institut de cancérologie de l'Ouest Angers, France
  • Clinique Sainte Catherine Avignon, France
  • Centre Hospitalier de la Côte Basque Bayonne, France
  • CHU Bordeaux - Hôpial Saint André Bordeaux, France
View all 33 locations
View Trial Details
Active, Not Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

NCT05843448

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, +12 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View Trial Details
Active, Not Recruiting

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

NCT05501054

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Duke Cancer Institute Durham, North Carolina, United States
  • Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • Mayo Clinic in Arizona - Phoenix ( Site 0043) Phoenix, Arizona, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 0035) Fullerton, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0005) Los Angeles, California, United States
  • University of California San Francisco ( Site 0010) San Francisco, California, United States
View all 188 locations
View Trial Details
Active, Not Recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine Gland Neoplasms, Endocrine System Diseases, +102 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 172 locations
View Trial Details
Active, Not Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +15 more
Locations
  • BCG Oncology Phoenix, Arizona, United States
  • Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
View Trial Details

Related conditions